Sichuan Kelun-Biotech Biopharmaceutical (Kelun-Biotech) completed its initial public offering and listing on The Stock Exchange of Hong Kong Limited. The Company raised gross proceeds of approximately $200 million after the full exercise of the over-allotment option from the global offering.
Kelun-Biotech is a biopharmaceutical company that researches, develops, manufactures and commercializes novel treatments for oncology, immunology and other therapeutic areas, with 14 drug candidates in clinical stage. Kelun-Biotech is one of the first companies to develop antibody drug conjugates (ADCs) and has over a decade of experience in ADC development, as well as an in-house developed ADC platform, OptiDC. S&C acted for the underwriters, Goldman Sachs, CLSA, Citigroup, ICBC and BOCOM, on both Hong Kong and U.S. law matters.
The S&C team was led by Gwen Wong, Kay Ian Ng and Ching-Yang Lin. The core team consists of associates Xi Rui, Mengli Wan, Bella Wang and Runtong Gong. Jeffrey Hochberg, Saul Brander and Tristan Hood advised on U.S. tax matters.